SCHEMBL450155

SCHEMBL450155

Cc1ccc(-n2c(C(C)N(C)C(=O)c3ccc4c(c3)OCO4)nc3ccc(Br)cc3c2=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
ATM Q13315 1/20 0.43
HTT P42858 3/20 0.43
USP2 O75604 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KDM4E B2RXH2 2/20 0.42
GAA P10253 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
MEN1 O00255 5/20 0.41
KMT2A Q03164 5/20 0.41
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
NR4A1 P22736 1/20 0.40
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
MC4R P32245 1/20 0.39
PPARG P37231 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL448885 0.89 ALDH1A1 (0.54) MAPTHTTUSP2SMN1; SMN2KDM4E
SCHEMBL449456 0.88 ALDH1A1 (0.45) MAPTHTTUSP2SMN1; SMN2KDM4E
SCHEMBL451808 0.87 SMN1; SMN2 (0.45) MAPTHTTUSP2SMN1; SMN2KDM4E
SCHEMBL449367 0.84 SMN1; SMN2 (0.47) MAPTHTTUSP2SMN1; SMN2KDM4E
SCHEMBL449751 0.84 ALDH1A1 (0.50) MAPTHTTUSP2SMN1; SMN2KDM4E
SCHEMBL448951 0.83 MAPT (0.46) MAPTATMSMN1; SMN2HPGDLMNA
SCHEMBL450532 0.82 ALDH1A1 (0.46) MAPTHTTUSP2SMN1; SMN2KDM4E
SCHEMBL452808 0.82 SMN1; SMN2 (0.47) MAPTHTTUSP2SMN1; SMN2KDM4E
SCHEMBL452237 0.82 ALDH1A1 (0.45) MAPTHTTUSP2SMN1; SMN2KDM4E
SCHEMBL451852 0.82 ALDH1A1 (0.45) MAPTHTTUSP2SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US disclosed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 MAPT 4075/4885ATM 3082/4885HTT 4552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.